To ask the Secretary of State for Health and Social Care, how much funding from the public purse was allocated to biomedical research into Myalgic Encephalomyelitis 2016-2017.
22 May 2018
In the period in question, the major National Institute for Health Research (NIHR) funding for biomedical research was through its Biomedical Research Centres and Units. These support research funded by the NIHR itself and also research funded by other public, charity and industry research funders. The level of funding for biomedical research into chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) for each financial year can be found in the table below. The funding for this research came from a combination of funders.
The NIHR Clinical Research Network (CRN) provides the infrastructure that allows high-quality clinical research funded by charities, research funders and life-sciences industry to be undertaken throughout the National Health Service. The level of funding for biomedical research into CFS/ME for each financial year can be found in the table below. The funding for this research came from a combination of the NIHR, the Medical Research Council (MRC) and medical research charities. Expenditure from the CRN coordinating centre itself is also outlined below:
CRN funding for research, £
Coordinating expenditure, £
The MRC spend on research directly relating to CFS/ME can be found in the following table. Research into CFS/ME is a continuing priority for the MRC.
The NIHR and the MRC welcomes funding applications for research into any aspect of human health, including biomedical research into CFS/ME. It is not usual practice to ring-fence funds for particular topics or conditions. Applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality. On this basis, it is not possible to say how much funding is planned in the current financial year.
The NIHR recognises that CFS/ME is a debilitating condition and is speaking with the United Kingdom CFS/ME Research Collaborative and patient representatives about how best we can support a joined up approach to high quality research into this complex disorder.